Development of In Vitro–In Vivo Correlation for Upadacitinib Extended-Release Tablet Formulation

Upadacitinib is a selective Janus Kinase 1 inhibitor which is being developed for the treatment of several inflammatory diseases including rheumatoid arthritis. Upadacitinib was evaluated in Phase 3 studies as an oral extended-release (ER) formulation administered once daily. The purpose of this stu...

Descripción completa

Detalles Bibliográficos
Autores principales: Mohamed, Mohamed-Eslam F., Trueman, Sheryl, Othman, Ahmed A., Han, Jian-Hwa, Ju, Tzuchi R., Marroum, Patrick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6814631/
https://www.ncbi.nlm.nih.gov/pubmed/31654328
http://dx.doi.org/10.1208/s12248-019-0378-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6814631/
https://www.ncbi.nlm.nih.gov/pubmed/31654328
http://dx.doi.org/10.1208/s12248-019-0378-y

Ejemplares similares